Company / Accounts Receivable
Amgen Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$9.6B
FY2025
5-year range
$4.9B / $9.6B
FY2021-FY2025
Trend
+41.1%
vs FY2024
Sector context
#7 of 115
Health Care
What the data says
Among 115 Health Care companies, Amgen is in the top 6% for accounts receivable. Improved from $7.3B to $9.6B over the past 2 years.
Based on SEC 10-K filings.
$9.6B in FY2025 with a 5-year CAGR of +16.2%. Top quartile in the Health Care sector.
Improved from $7.3B to $9.6B over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +19.8%
- 5-Year CAGR
- +16.2%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 115This company $9.6B Sector average $1.1B
▼
+755.0% above sector average
Key checks
Key Insights
- 5-year CAGR of +16.2%, indicating consistent growth.
- In FY2025, accounts receivable increased 41.1% year-over-year.
- Ranks #7 out of 115 companies in the Health Care sector.
- Lowest accounts receivable in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.55 (distress zone, below 1.8 threshold)
- Strong return on equity: 72.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.6B | +41.1% |
| FY2024 | $6.8B | -6.7% |
| FY2023 | $7.3B | +30.6% |
| FY2022 | $5.6B | +13.6% |
| FY2021 | $4.9B | +8.2% |
| FY2020 | $4.5B | +11.5% |
| FY2019 | $4.1B | +13.3% |
| FY2018 | $3.6B | +10.6% |
| FY2017 | $3.2B | +2.3% |
| FY2016 | $3.2B | +5.7% |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026